All News
Great Lectures; Great Presentations
Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Read Article
COVID Virus Persistence with DMARD Use
MedPage Today
Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.
Read Article
Review of GLP-1 Receptor Agonists in Psoriasis
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed cardiometabolic medicine and are now attracting intense interest in inflammatory disorders.
Read Article
FDA Targeting the Safety of Avacopan
The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market.
Read Article
Which autoimmune condition carries the highest relative risk for lymphoma? Test your knowledge in the latest RheumIQ quiz at https://t.co/TBlB4pmnKa https://t.co/sx8fpdHgHN
Dr. John Cush RheumNow ( View Tweet)
Review of GLP-1 Receptor Agonists in Psoriasis
Psoriasis is a chronic immune-mediated inflammatory disease plaqued by systemic comorbidities that increase morbidity, mortality, and treatment complexity. Obesity is a significant contributor to psoriatic disease. https://t.co/R1Uutdjcvz
Dr. John Cush RheumNow ( View Tweet)
FDA Targeting the Safety of Avacopan
The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market. https://t.co/4PyIoqwNIL
Dr. John Cush RheumNow ( View Tweet)
APR: Steroids
https://t.co/FxqGaijo6w https://t.co/OrybGNXsdf
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
https://t.co/RFECflCUgf https://t.co/Da7D6KpN6q
Dr. John Cush RheumNow ( View Tweet)
Synovial tissue study from 244 #OA pts undergoing surgery, finds variable synovial pathotypes - High-grade synovitis in 64% (55% lympho-myeloid, 12% diffuse-myeloid, 33% pauci-immune). Lympho-myeloid had highest inflammation, incr by high BMI. https://t.co/cc0Z3KWtY0 https://t.co/zf7r23KGCy
Dr. John Cush RheumNow ( View Tweet)
RA is significantly associated with an increased risk of osteoporotic fractures (OPF) -RR 1.47 (1.32–1.64), for both female (1.39) & male(1.69) pts. Metanalysis of OPF in RA (7 cohort studies, 12,408pts). https://t.co/XP719A3ZM6 https://t.co/40phL7K9EB
Dr. John Cush RheumNow ( View Tweet)
Neoplasia and Autoimmune Disease
Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune https://t.co/uIsVl1N1hH
Dr. John Cush RheumNow ( View Tweet)
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA
After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/mEaUcBD2ZK
Dr. John Cush RheumNow ( View Tweet)
Mexico study of SLE mortality in kids. Betw 2000-23, SLE accounted for 637/280,334 child deaths. Females (80%) had 4X higher deaths than males (ASMR 0.13 vs 0.03). No consistent trend in time for mortality. https://t.co/gkoXG90nLx https://t.co/BB0JhTHFKf
Dr. John Cush RheumNow ( View Tweet)
A man spends 50 years teaching at MIT.
He knows his time is running out.
So he records one last lecture — everything he knows, distilled into a single hour.
He died 5 months later.
This is that lecture.
The most important hour you'll watch this week. 👇
Bookmark it for later https://t.co/tRUH05ysSt
Suryansh Tiwari Suryanshti777 ( View Tweet)
APR: Methotrexate
Companion slide deck for the Advanced Practice Rheum: Methotrexate video, featuring Dr. Jack Cush.
https://t.co/8422FKN4dq https://t.co/6gVS7dA8Gi
Links:
Dr. John Cush RheumNow ( View Tweet)
True or False: Low-dose aspirin given at giant cell arteritis diagnosis is associated with a lower risk of major adverse cardiovascular events. Put your answer to the test in the latest RheumIQ quiz at https://t.co/XLPVoyCbLB. https://t.co/C5CSwuv5mF
Dr. John Cush RheumNow ( View Tweet)
Study of 216 RA pts - Serum IL-8 independently assoc w/ RA Dz activity. CRP & IL-6 significantly associated w/ higher IL-8 levels, but RF & CCP did not. IL-8 also correlated w/ CV risk (SCORE2) & carotid intima media thickness https://t.co/aqUoAeXFFP https://t.co/ZW7OAx8YGK
Links:
Dr. John Cush RheumNow ( View Tweet)
Dental study from India assessed periodontal Dz (PD) in 170 RA vs 170 non-RA pts. RA had more PD, ^ESR, more mild PD (39% v 29%). DAS-28 correlated w/ PD severity. Pts w/ periodontitis had 3X ods of RA (OR = 2.9) /https://t.co/bvOnFzbRcd https://t.co/cSxfiIR4iS
Links:
Dr. John Cush RheumNow ( View Tweet)
